<ul>
<li>關注美聯儲降息後的三隻小盤股</li>
</ul>
<p>Emergent Biosolutions（紐約證券交易所代碼：EBS）於週二召開了 2026 年股東年會，股東們對董事選舉、審計師確認、管理層薪酬以及增加公司股票激勵計劃可用股份的修正案進行了投票。管理層還回顧了 2025 年在其所稱的多年度轉型努力中取得的進展。</p>
<p>獲取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
<h2>管理層強調 2025 年轉型進展</h2>
<p>董事會主席 Zsolt Harsanyi 博士表示，公司在 2025 年 “顯著推進” 了其轉型和變革計劃，提到通過 “精簡高效的商業模式、強勁的運營業績、利潤率改善和債務減少” 來增強 Emergent 的財務狀況。他補充説，董事會和領導團隊對公司能夠通過 “推動長期增長和盈利能力” 來創造股東價值充滿信心，同時繼續其 “保護和拯救生命” 的使命。</p>
<ul>
<li>大幅反彈即將來臨？關注三隻分析師推薦的股票</li>
</ul>
<p>總裁兼首席執行官 Joe Papa 表示，Emergent 在 2025 年 “在執行我們的多年度轉型優先事項方面取得了顯著進展”，指出運營利潤率改善、“強勁的調整後息税折舊攤銷前利潤為 2.05 億美元”、現金流增加和債務槓桿減少。</p>
<p>Papa 表示，在通過 “戰略性剝離和運營舉措” 穩定業務後，公司在 2025 年進一步增強了財務狀況，並繼續推進其轉型計劃。</p>
<h2>2025 年財務和運營里程碑</h2>
<ul>
<li>隨着市場輪動繼續，關注這四隻超買股票</li>
</ul>
<p>在他的發言中，Papa 概述了他歸功於公司團隊的幾項成就，包括流動性改善和債務減少。他表示，Emergent：</p>
<ul>
<li>現金餘額增加了 1 億美元</li>
<li>債務減少了 1.1 億美元</li>
<li>實現了 “強勁的收益和現金流”</li>
</ul>
<p>Papa 還表示，公司獲得了 “多個醫療對策合同，以支持美國及國際的生物防禦準備”。在公司的納洛酮業務中，他表示 Emergent 通過收購 Kloxxado 鼻用噴霧劑（8 毫克）的商業權利擴大了其產品組合，並 “保持了 NARCAN 鼻用噴霧劑的市場領導地位”。Papa 還提到 Emergent“宣佈與瑞士火箭公司達成投資協議”。</p>
<p>他説，公司在 “患者安全、質量和合規性” 的明確關注下，採取的行動使 Emergent 能夠追求 “戰略轉型，以實現長期增長和盈利能力”。</p>
<h2>2026 年關注領域：管道、納洛酮擴展和國際增長</h2>
<p>展望未來，Papa 表示，憑藉更強的現金和流動性狀況，Emergent 計劃在其醫療對策和納洛酮業務中投資於收入增長驅動因素。他表示，公司 2026 年的優先事項包括推進內部管道，推出旨在減少阿片類藥物過量死亡的額外納洛酮產品線擴展，以及加速國際增長。</p>
<p>Papa 還表示，Emergent 打算追求 “有針對性的收購和利用我們基礎設施及能力的外部機會”。他補充説，他對 Emergent 成為 “解決全球社區公共衞生威脅的領導者” 的願景保持樂觀。</p>
<h2>股東批准所有提案；董事當選</h2>
<p>在會議期間，高級副總裁、總法律顧問和公司秘書 Jessica Perl 概述了議程上的四項提案：</p>
<ul>
<li>選舉 Sujata Dayal、Dr. Zsolt Harsanyi、Joseph Papa 和 John D. Fowler, Jr.為二級董事，任期至 2029 年股東年會結束</li>
<li>確認 Ernst &amp; Young LLP 為截至 2026 年 12 月 31 日的財政年度獨立註冊公共會計師</li>
<li>對 2025 年指定高管的薪酬進行諮詢投票</li>
<li>批准修正案以增加公司修訂和重述的股票激勵計劃下可用於獎勵的股份</li>
</ul>
<p>Harsanyi 隨後宣佈初步投票結果，表示每位董事提名人均獲得 “投票的多數”，並當選。他表示，審計師確認提案和高管薪酬諮詢投票以及股票激勵計劃股份增加修正案均獲得 “多數投票”。</p>
<p>Harsanyi 表示，Emergent 預計將在會議後四個工作日內向證券交易委員會提交的 8-K 表格中報告最終投票結果。</p>
<h2>未提交股東提問</h2>
<p>在正式業務結束後，公司開啓了問答環節。主持人表示沒有收到任何問題，虛擬股東年會隨即結束。</p>
<h2>關於 Emergent Biosolutions（紐約證券交易所代碼：EBS）</h2>
<p>Emergent BioSolutions 是一家全球專注於開發、生產和商業化醫療對策及特殊產品的生物製藥公司，旨在應對公共衞生威脅。公司的產品組合包括疫苗、抗體療法和關鍵護理產品，旨在保護人們免受生物、化學和新興傳染病威脅。Emergent 與政府機構（包括美國國防部和生物醫學先進研究與發展局（BARDA））建立了長期合作關係，以支持國家準備計劃。</p>
<p>Emergent 產品線中的關鍵商業產品包括 BioThrax（炭疽疫苗吸附劑）、ACAM2000（天花疫苗）和 Vaxchora（霍亂疫苗），以及治療性產品如 Anthrasil（炭疽免疫球蛋白）和用於阿片類藥物過量逆轉的納洛酮鼻用噴霧劑 Narcan。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Emergent Biosolutions</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在 Emergent Biosolutions 嗎？</h2>
<p>在考慮 Emergent Biosolutions 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Emergent Biosolutions 並不在名單上。</p>
<p>雖然 Emergent Biosolutions 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

動態生物技術與基因組 ETF - Invesco

IBBQ

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

2 倍做多納斯達克生物技術 ETF - ProShares

<p>Emergent BioSolutions 舉行了 2026 年年度股東大會，股東們批准了所有提案，包括董事選舉和增加股票激勵計劃股份的修訂。管理層報告了其多年轉型的顯著進展，強調了財務指標的改善，如 2.05 億美元的調整後 EBITDA 和減少的債務。公司計劃在 2026 年專注於推進其產品管線、納洛酮擴展和國際增長，同時也將追求戰略收購。所有董事提名人均已當選，審計師也已獲得批准，適用於截至 2026 年 12 月 31 日的財政年度</p>

<ul>
<li>3 Small-Cap Stocks to Watch After the Fed’s Rate Cuts</li>
</ul>
<div class="lb-trans"><ul>
<li>關注美聯儲降息後的三隻小盤股</li>
</ul>
</div><p>Emergent Biosolutions NYSE: EBS on Tuesday held its 2026 Annual Meeting of Stockholders, where shareholders voted on director elections, auditor ratification, executive compensation, and an amendment to increase shares available under the company’s stock incentive plan. Management also reviewed progress made in 2025 as part of what it described as a multi-year turnaround effort.</p>
<div class="lb-trans"><p>Emergent Biosolutions（紐約證券交易所代碼：EBS）於週二召開了 2026 年股東年會，股東們對董事選舉、審計師確認、管理層薪酬以及增加公司股票激勵計劃可用股份的修正案進行了投票。管理層還回顧了 2025 年在其所稱的多年度轉型努力中取得的進展。</p>
</div><p>Get <strong>Emergent Biosolutions</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Emergent Biosolutions</strong> 的提醒：</p>
</div><h2>Management highlights 2025 turnaround progress</h2>
<div class="lb-trans"><h2>管理層強調 2025 年轉型進展</h2>
</div><p>Board Chair Dr. Zsolt Harsanyi said the company “significantly progressed” its turnaround and transformation plan in 2025, citing efforts to strengthen Emergent’s financial position through “a lean and efficient business model, strong operating results, margin improvements, and debt reduction.” He added that the board and leadership team remain confident the company can create shareholder value by “driving long-term growth and profitability” while continuing its mission to “protect and save lives.”</p>
<div class="lb-trans"><p>董事會主席 Zsolt Harsanyi 博士表示，公司在 2025 年 “顯著推進” 了其轉型和變革計劃，提到通過 “精簡高效的商業模式、強勁的運營業績、利潤率改善和債務減少” 來增強 Emergent 的財務狀況。他補充説，董事會和領導團隊對公司能夠通過 “推動長期增長和盈利能力” 來創造股東價值充滿信心，同時繼續其 “保護和拯救生命” 的使命。</p>
</div><ul>
<li>Big Rallies Brewing? 3 Analyst Favorites to Watch Closely</li>
</ul>
<div class="lb-trans"><ul>
<li>大幅反彈即將來臨？關注三隻分析師推薦的股票</li>
</ul>
</div><p>President and CEO Joe Papa said Emergent made “significant progress executing our multi-year turnaround priorities” during 2025, pointing to improved operating margins, “strong adjusted EBITDA of $205 million,” increased cash flow, and reduced debt leverage.</p>
<div class="lb-trans"><p>總裁兼首席執行官 Joe Papa 表示，Emergent 在 2025 年 “在執行我們的多年度轉型優先事項方面取得了顯著進展”，指出運營利潤率改善、“強勁的調整後息税折舊攤銷前利潤為 2.05 億美元”、現金流增加和債務槓桿減少。</p>
</div><p>Papa said that after stabilizing the business through “strategic divestitures and operational initiatives,” the company further strengthened its financial position in 2025 and continued advancing its turnaround plan.</p>
<div class="lb-trans"><p>Papa 表示，在通過 “戰略性剝離和運營舉措” 穩定業務後，公司在 2025 年進一步增強了財務狀況，並繼續推進其轉型計劃。</p>
</div><h2>Financial and operational milestones cited for 2025</h2>
<div class="lb-trans"><h2>2025 年財務和運營里程碑</h2>
</div><ul>
<li>Watch These 4 Overbought Stocks As Market Rotation Continues</li>
</ul>
<div class="lb-trans"><ul>
<li>隨着市場輪動繼續，關注這四隻超買股票</li>
</ul>
</div><p>In his remarks, Papa outlined several accomplishments he attributed to the company’s team, including improved liquidity and debt reduction. He said Emergent:</p>
<div class="lb-trans"><p>在他的發言中，Papa 概述了他歸功於公司團隊的幾項成就，包括流動性改善和債務減少。他表示，Emergent：</p>
</div><ul>
<li>Improved its cash balance by $100 million</li>
<li>Reduced debt by $110 million</li>
<li>Delivered “strong earnings and cash flow”</li>
</ul>
<div class="lb-trans"><ul>
<li>現金餘額增加了 1 億美元</li>
<li>債務減少了 1.1 億美元</li>
<li>實現了 “強勁的收益和現金流”</li>
</ul>
</div><p>Papa also said the company secured “multiple medical countermeasures contract awards for biodefense preparedness in the U.S. and internationally.” In the company’s naloxone business, he said Emergent expanded its portfolio by acquiring the commercial rights to Kloxxado nasal spray (8 mg) and “maintained market leadership for NARCAN nasal spray.” Papa also noted Emergent “announced an investment agreement with Swiss Rockets.”</p>
<div class="lb-trans"><p>Papa 還表示，公司獲得了 “多個醫療對策合同，以支持美國及國際的生物防禦準備”。在公司的納洛酮業務中，他表示 Emergent 通過收購 Kloxxado 鼻用噴霧劑（8 毫克）的商業權利擴大了其產品組合，並 “保持了 NARCAN 鼻用噴霧劑的市場領導地位”。Papa 還提到 Emergent“宣佈與瑞士火箭公司達成投資協議”。</p>
</div><p>He said the company’s actions, alongside its stated focus on “patient safety, quality, and compliance,” position Emergent to pursue “strategic transformation for long-term growth and profitability.”</p>
<div class="lb-trans"><p>他説，公司在 “患者安全、質量和合規性” 的明確關注下，採取的行動使 Emergent 能夠追求 “戰略轉型，以實現長期增長和盈利能力”。</p>
</div><h2>2026 focus areas: pipeline, naloxone extensions, and international growth</h2>
<div class="lb-trans"><h2>2026 年關注領域：管道、納洛酮擴展和國際增長</h2>
</div><p>Looking ahead, Papa said that with a stronger cash and liquidity position, Emergent plans to invest in revenue growth drivers across its medical countermeasures and naloxone businesses. He said the company’s 2026 priorities include advancing its internal pipeline, launching additional naloxone line extensions aimed at reducing opioid overdose deaths, and accelerating international growth.</p>
<div class="lb-trans"><p>展望未來，Papa 表示，憑藉更強的現金和流動性狀況，Emergent 計劃在其醫療對策和納洛酮業務中投資於收入增長驅動因素。他表示，公司 2026 年的優先事項包括推進內部管道，推出旨在減少阿片類藥物過量死亡的額外納洛酮產品線擴展，以及加速國際增長。</p>
</div><p>Papa also said Emergent intends to pursue “targeted acquisitions and external opportunities that leverage our infrastructure and capabilities.” He added that he remains optimistic about Emergent’s vision to be “the leader in solving public health threats for communities around the world.”</p>
<div class="lb-trans"><p>Papa 還表示，Emergent 打算追求 “有針對性的收購和利用我們基礎設施及能力的外部機會”。他補充説，他對 Emergent 成為 “解決全球社區公共衞生威脅的領導者” 的願景保持樂觀。</p>
</div><h2>Shareholders approve all proposals; directors elected</h2>
<div class="lb-trans"><h2>股東批准所有提案；董事當選</h2>
</div><p>During the meeting, Senior Vice President, General Counsel, and Corporate Secretary Jessica Perl outlined four proposals on the agenda:</p>
<div class="lb-trans"><p>在會議期間，高級副總裁、總法律顧問和公司秘書 Jessica Perl 概述了議程上的四項提案：</p>
</div><ul>
<li>Election of Sujata Dayal, Dr. Zsolt Harsanyi, Joseph Papa, and John D. Fowler, Jr. as Class II directors for terms expiring at the 2029 Annual Meeting of Stockholders</li>
<li>Ratification of Ernst &amp; Young LLP as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026</li>
<li>Advisory vote to approve the 2025 compensation of named executive officers</li>
<li>Approval of an amendment to increase shares available for awards under the company’s Amended and Restated Stock Incentive Plan</li>
</ul>
<div class="lb-trans"><ul>
<li>選舉 Sujata Dayal、Dr. Zsolt Harsanyi、Joseph Papa 和 John D. Fowler, Jr.為二級董事，任期至 2029 年股東年會結束</li>
<li>確認 Ernst &amp; Young LLP 為截至 2026 年 12 月 31 日的財政年度獨立註冊公共會計師</li>
<li>對 2025 年指定高管的薪酬進行諮詢投票</li>
<li>批准修正案以增加公司修訂和重述的股票激勵計劃下可用於獎勵的股份</li>
</ul>
</div><p>Harsanyi later announced preliminary voting results, stating each director nominee received “a plurality of the votes cast” and was elected. He said the auditor ratification proposal received “a majority of the votes cast,” as did the advisory vote on executive compensation and the stock incentive plan share increase amendment.</p>
<div class="lb-trans"><p>Harsanyi 隨後宣佈初步投票結果，表示每位董事提名人均獲得 “投票的多數”，並當選。他表示，審計師確認提案和高管薪酬諮詢投票以及股票激勵計劃股份增加修正案均獲得 “多數投票”。</p>
</div><p>Harsanyi said Emergent expects to report final voting results in a Form 8-K filed with the Securities and Exchange Commission within four business days of the meeting.</p>
<div class="lb-trans"><p>Harsanyi 表示，Emergent 預計將在會議後四個工作日內向證券交易委員會提交的 8-K 表格中報告最終投票結果。</p>
</div><h2>No shareholder questions submitted</h2>
<div class="lb-trans"><h2>未提交股東提問</h2>
</div><p>After the formal business concluded, the company opened a question-and-answer portion of the meeting. The operator said no questions were received, and the virtual annual meeting was then concluded.</p>
<div class="lb-trans"><p>在正式業務結束後，公司開啓了問答環節。主持人表示沒有收到任何問題，虛擬股東年會隨即結束。</p>
</div><h2>About Emergent Biosolutions NYSE: EBS</h2>
<div class="lb-trans"><h2>關於 Emergent Biosolutions（紐約證券交易所代碼：EBS）</h2>
</div><p>Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.</p>
<div class="lb-trans"><p>Emergent BioSolutions 是一家全球專注於開發、生產和商業化醫療對策及特殊產品的生物製藥公司，旨在應對公共衞生威脅。公司的產品組合包括疫苗、抗體療法和關鍵護理產品，旨在保護人們免受生物、化學和新興傳染病威脅。Emergent 與政府機構（包括美國國防部和生物醫學先進研究與發展局（BARDA））建立了長期合作關係，以支持國家準備計劃。</p>
</div><p>Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.</p>
<div class="lb-trans"><p>Emergent 產品線中的關鍵商業產品包括 BioThrax（炭疽疫苗吸附劑）、ACAM2000（天花疫苗）和 Vaxchora（霍亂疫苗），以及治療性產品如 Anthrasil（炭疽免疫球蛋白）和用於阿片類藥物過量逆轉的納洛酮鼻用噴霧劑 Narcan。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Emergent Biosolutions</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Emergent Biosolutions</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Emergent Biosolutions Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Emergent Biosolutions 嗎？</h2>
</div><p>Before you consider Emergent Biosolutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Emergent Biosolutions 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Emergent Biosolutions 並不在名單上。</p>
</div><p>While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Emergent Biosolutions 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved

Market Beat

Emergent Biosolutions

Invesco Nasdaq Biotechnology ETF

Emergent BioSolutions 在 2026 年年度會議上提供了轉型更新；所有提案均已獲批